Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Gynecology

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 123 articles:
HTML format
Text format



Single Articles


    June 2019
  1. CECHOVA M, Chocholaty M, Zima T, Babjuk M, et al
    The Significance of Pregnancy-associated Plasma Protein a Serum Concentration in Clear Cell Renal Cell Carcinoma.
    Anticancer Res. 2019;39:3249-3253.
    PubMed     Text format     Abstract available


  2. LIN YC, Chen RY, Liang JA, Hung YC, et al
    Immunohistochemical Biomarkers of Survival in Patients With Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy.
    Anticancer Res. 2019;39:3231-3240.
    PubMed     Text format     Abstract available


  3. GOSSET M, Chargari C, Bentivegna E, Leary A, et al
    Should We Cease to Perform Salvage Hysterectomy After Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer?
    Anticancer Res. 2019;39:2919-2926.
    PubMed     Text format     Abstract available


  4. JUNG YY, Woo HY, Kim HS
    Targeted Genomic Sequencing Reveals Novel TP53 In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.
    Anticancer Res. 2019;39:2883-2889.
    PubMed     Text format     Abstract available


  5. CHEN SW, Liang JA, Hung YC, Yeh LS, et al
    Effectiveness of Image-guided Brachytherapy in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy.
    Anticancer Res. 2019;39:3015-3024.
    PubMed     Text format     Abstract available


    May 2019
  6. RATIU D, Luncescu C, Morgenstern B, Eichler C, et al
    Comparison of Minimally Invasive Surgery and Abdominal Surgery Among Patients With Cervical Cancer.
    Anticancer Res. 2019;39:2661-2664.
    PubMed     Text format     Abstract available


  7. CUCCIA F, Mortellaro G, Cespuglio D, Valenti V, et al
    A Case Report of Adult Pineoblastoma Occurring in a Pregnant Woman.
    Anticancer Res. 2019;39:2627-2631.
    PubMed     Text format     Abstract available


  8. BEDKOWSKA GE, Piskor B, Gacuta E, Zajkowska M, et al
    Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients - ROC Analysis.
    Anticancer Res. 2019;39:2575-2582.
    PubMed     Text format     Abstract available


  9. GADDUCCI A, Giuliani D, Cosio S, Lissoni A, et al
    Clinical Outcome of Patients With Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study.
    Anticancer Res. 2019;39:2513-2517.
    PubMed     Text format     Abstract available


  10. CHRISTENSEN MV, Hogdall C, Jensen SG, Lokman N, et al
    Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer.
    Anticancer Res. 2019;39:2475-2482.
    PubMed     Text format     Abstract available


  11. PIRES LV, Yi Y, Cheng JC, Pizzolato LS, et al
    Lapatinib Inhibits Amphiregulin-induced BeWo Choriocarcinoma Cell Proliferation by Reducing ERK1/2 and AKT Signaling Pathways.
    Anticancer Res. 2019;39:2377-2383.
    PubMed     Text format     Abstract available


  12. KIM JY, Kim SH, Kim HS
    Promoter Methylation Down-regulates Osteoprotegerin Expression in Ovarian Carcinoma.
    Anticancer Res. 2019;39:2361-2367.
    PubMed     Text format     Abstract available


  13. KORHEGYI Z, Rozsa D, Hajdu I, Bodnar M, et al
    Synthesis of (68)Ga-Labeled Biopolymer-based Nanoparticle Imaging Agents for Positron-emission Tomography.
    Anticancer Res. 2019;39:2415-2427.
    PubMed     Text format     Abstract available


    April 2019
  14. MIYAMOTO M, Takano M, Tsuda H, Ishibashi H, et al
    Zone Formation of Lymphocyte Infiltration at the Invasive Front Results in the Prolonged Survival of Individuals With Endometrial Serous Carcinoma and Endometrioid Carcinoma With Serous Component.
    Anticancer Res. 2019;39:2085-2089.
    PubMed     Text format     Abstract available


  15. CHECK JH, Check D, Poretta T
    Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
    Anticancer Res. 2019;39:1923-1926.
    PubMed     Text format     Abstract available


  16. KUBOTA Y, Ohno T, Kawashima M, Murata K, et al
    Development of a Vaginal Immobilization Device: A Treatment-planning Study of Carbon-ion Radiotherapy and Intensity-modulated Radiation Therapy for Uterine Cervical Cancer.
    Anticancer Res. 2019;39:1915-1921.
    PubMed     Text format     Abstract available


  17. JELENIEWICZ W, Cybulski M, Nowakowski A, Stenzel-Bembenek A, et al
    MMP-2 mRNA Expression in Ovarian Cancer Tissues Predicts Patients' Response to Platinum-Taxane Chemotherapy.
    Anticancer Res. 2019;39:1821-1827.
    PubMed     Text format     Abstract available


    March 2019
  18. REZNICZEK GA, Grunwald C, Hilal Z, Scheich J, et al
    ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).
    Anticancer Res. 2019;39:1267-1273.
    PubMed     Text format     Abstract available


    February 2019
  19. MATSUOKA H, Nakamura K, Matsubara Y, Ida N, et al
    Sarcopenia Is Not a Prognostic Factor of Outcome in Patients With Cervical Cancer Undergoing Concurrent Chemoradiotherapy or Radiotherapy.
    Anticancer Res. 2019;39:933-939.
    PubMed     Text format     Abstract available


  20. UNO T, Kanazawa A, Nemoto MW, Harada R, et al
    Radiation Therapy for Extrapelvic Lymph Node Recurrence After Curative Treatment for Cervical Cancer.
    Anticancer Res. 2019;39:891-895.
    PubMed     Text format     Abstract available


  21. TRYBUS W, Krol T, Trybus E, Stachurska A, et al
    Emodin Induces Death in Human Cervical Cancer Cells Through Mitotic Catastrophe.
    Anticancer Res. 2019;39:679-686.
    PubMed     Text format     Abstract available


  22. LEGROS M, Margueritte F, Tardieu A, Deluche E, et al
    Para-aortic Lymph Node Invasion in High-risk Endometrial Cancer: Performance of (18)FDG PET-CT.
    Anticancer Res. 2019;39:619-625.
    PubMed     Text format     Abstract available


  23. YAMAMOTO M, Suzuki S, Togashi K, Sanomachi T, et al
    AS602801 Sensitizes Ovarian Cancer Stem Cells to Paclitaxel by Down-regulating MDR1.
    Anticancer Res. 2019;39:609-617.
    PubMed     Text format     Abstract available


  24. AHTIKOSKI AM, Kangas J, Salonen R, Puistola U, et al
    Cytoplasmic Keap1 Expression Is Associated With Poor Prognosis in Endometrial Cancer.
    Anticancer Res. 2019;39:585-590.
    PubMed     Text format     Abstract available


  25. RASK L, Hogdall CK, Kjaer SK, Christensen L, et al
    Association of CD31 and p53 With Survival of Ovarian Cancer Patients.
    Anticancer Res. 2019;39:567-576.
    PubMed     Text format     Abstract available


  26. SIDERIS M, Emin EI, Abdullah Z, Hanrahan J, et al
    The Role of KRAS in Endometrial Cancer: A Mini-Review.
    Anticancer Res. 2019;39:533-539.
    PubMed     Text format     Abstract available


    January 2019
  27. KLAT J, Mladenka A, Dvorackova J, Bajsova S, et al
    L1CAM as a Negative Prognostic Factor in Endometrioid Endometrial Adenocarcinoma FIGO Stage IA-IB.
    Anticancer Res. 2019;39:421-424.
    PubMed     Text format     Abstract available


  28. SAKAGUCHI M, Maebayashi T, Aizawa T, Ishibashi N, et al
    Risk Factors for Sacral Insufficiency Fractures in Cervical Cancer After Whole Pelvic Radiation Therapy.
    Anticancer Res. 2019;39:361-367.
    PubMed     Text format     Abstract available


  29. KIM JH, Yoon YS, Kim JC, Kim YM, et al
    Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer.
    Anticancer Res. 2019;39:313-318.
    PubMed     Text format     Abstract available


  30. SHIMOKAWA M, Hayashi T, Kogawa T, Matsui R, et al
    Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy.
    Anticancer Res. 2019;39:225-230.
    PubMed     Text format     Abstract available


  31. ERNSTSON A, Asciutto KC, Sturesson J, Noren J, et al
    Detection of HPV mRNA in Self-collected Vaginal Samples Among Women at 69-70 Years of Age.
    Anticancer Res. 2019;39:381-386.
    PubMed     Text format     Abstract available


    December 2018
  32. EOH KJ, Park HS, Park JS, Lee ST, et al
    Distinct Clinical Courses of Epithelial Ovarian Cancer with Mutations in BRCA1 5' and 3' Exons.
    Anticancer Res. 2018;38:6947-6953.
    PubMed     Text format     Abstract available


  33. YAMAMOTO M, Suzuki S, Togashi K, Sanomachi T, et al
    AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel.
    Anticancer Res. 2018;38:6699-6706.
    PubMed     Text format     Abstract available


  34. LARBRE V, Alyami M, Mercier F, Vantard N, et al
    No Renal Toxicity After Repeated Treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Unresectable Peritoneal Metastasis.
    Anticancer Res. 2018;38:6869-6875.
    PubMed     Text format     Abstract available


  35. DE LIMA TM, DE Azevedo Focchi GR, DE Almeida BC, Belfort-Mattos PN, et al
    Expression of CK7 and CDKN2 in Cervical Intraepithelial Neoplasia and Correlation with Clinical Outcome.
    Anticancer Res. 2018;38:6673-6681.
    PubMed     Text format     Abstract available


    November 2018
  36. PETRU E, Huber C, Sampl E, Haas J, et al
    Comparison of Primary Tumor Size in Stage I and III Epithelial Ovarian Cancer.
    Anticancer Res. 2018;38:6507-6511.
    PubMed     Text format     Abstract available


    October 2018
  37. DILLEY J, Pratt P, Kyrgiou M, Flott K, et al
    Current and Future Use of Radiological Images in the Management of Gynecological Malignancies - A Survey of Practice in the UK.
    Anticancer Res. 2018;38:5867-5876.
    PubMed     Text format     Abstract available


  38. GRABOWSKI JP, Richter R, Rittmeister H, Chekerov R, et al
    Impact of Body Mass Index (BMI) on Chemotherapy-associated Toxicity in Ovarian Cancer Patients. A Pooled Analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) Databank on 1,213 Patients.
    Anticancer Res. 2018;38:5853-5858.
    PubMed     Text format     Abstract available


  39. TSIAMBAS E, Riziotis C, Mastronikolis NS, Peschos D, et al
    Comparative p16(IKN4A) Expression in Laryngeal Carcinoma and Cervical Cancer Precursors: A Real-time Grid-based Immunocytochemistry Analysis.
    Anticancer Res. 2018;38:5805-5810.
    PubMed     Text format     Abstract available


  40. KOUKOURAKIS MI, Kontomanolis E, Sotiropoulou M, Mitrakas A, et al
    Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200.
    Anticancer Res. 2018;38:5739-5745.
    PubMed     Text format     Abstract available


  41. AFROZE SH, Peddaboina C, McDowell AB Jr, Ashraf AHMZ, et al
    Differential Effects of In Vitro Treatment with Cinobufotalin on Three Types of Ovarian Cancer Cells.
    Anticancer Res. 2018;38:5717-5724.
    PubMed     Text format     Abstract available


    September 2018
  42. LAFLEUR J, Hefler-Frischmuth K, Grimm C, Schwameis R, et al
    Prognostic Value of Serum Creatinine Levels in Patients with Epithelial Ovarian Cancer.
    Anticancer Res. 2018;38:5127-5130.
    PubMed     Text format     Abstract available


  43. ZHU Z, Zhao L, Brittingham A, Bai Q, et al
    Trichomonas Vaginalis Inhibits HeLa Cell Growth Through Modulation of Critical Molecules for Cell Proliferation and Apoptosis.
    Anticancer Res. 2018;38:5079-5086.
    PubMed     Text format     Abstract available


  44. PARK CK, Kim HS
    Clinicopathological Characteristics of Ovarian Metastasis from Colorectal and Pancreatobiliary Carcinomas Mimicking Primary Ovarian Mucinous Tumor.
    Anticancer Res. 2018;38:5465-5473.
    PubMed     Text format     Abstract available


  45. MENDIOLA M, Redondo A, Heredia-Soto V, Herranz J, et al
    Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Anticancer Res. 2018;38:5393-5400.
    PubMed     Text format     Abstract available


  46. SMOLARZ B, Michalska MM, Samulak D, Wojcik L, et al
    Studies of Correlations Between Single Nucleotide Polymorphisms of DNA Repair Genes and Endometrial Cancer in Polish Women.
    Anticancer Res. 2018;38:5223-5229.
    PubMed     Text format     Abstract available


  47. ASHRAF AHMZ, Afroze SH, Yamauchi K, Zawieja DC, et al
    Differential Mechanism of Action of 3,4',7-O-trimethylquercetin in Three Types of Ovarian Cancer Cells.
    Anticancer Res. 2018;38:5131-5137.
    PubMed     Text format     Abstract available


    August 2018
  48. PARASHKEVOVA A, Sehouli J, Richter R, Dimitrova D, et al
    Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.
    Anticancer Res. 2018;38:4865-4870.
    PubMed     Text format     Abstract available


  49. THIEME SF, Collettini F, Sehouli J, Biocca L, et al
    Preoperative Evaluation of Myometrial Invasion in Endometrial Carcinoma: Prospective Intra-individual Comparison of Magnetic Resonance Volumetry, Diffusion-weighted and Dynamic Contrast-enhanced Magnetic Resonance Imaging.
    Anticancer Res. 2018;38:4813-4817.
    PubMed     Text format     Abstract available


  50. PRODROMIDOU A, Machairas N, Spartalis E, Kostakis ID, et al
    Transperitoneal Versus Extraperitoneal Laparoscopic Lymphadenectomy for Gynecological Malignancies: A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:4677-4681.
    PubMed     Text format     Abstract available


  51. TOGASHI K, Okada M, Yamamoto M, Suzuki S, et al
    A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel.
    Anticancer Res. 2018;38:4535-4542.
    PubMed     Text format     Abstract available


    July 2018
  52. IZUCHI D, Fukagawa S, Yotsumoto F, Shigekawa K, et al
    Association of Serum HB-EGF Value and Response to Chemotherapy in Patients with Recurrent Ovarian Cancer.
    Anticancer Res. 2018;38:4347-4351.
    PubMed     Text format     Abstract available


  53. TAKAHASHI Y, Hamasaki M, Aoki M, Koga K, et al
    Activated EphA2 Processing by MT1-MMP Is Involved in Malignant Transformation of Ovarian Tumours In Vivo.
    Anticancer Res. 2018;38:4257-4266.
    PubMed     Text format     Abstract available


  54. ASCIUTTO KC, Forslund O, Borgfeldt C
    Prevalence of High-risk HPV in Postmenopausal Women with Benign Cervical Cytology - A Population-based Cohort Study.
    Anticancer Res. 2018;38:4221-4228.
    PubMed     Text format     Abstract available


  55. ARIMA R, Marttila M, Hautakoski A, Arffman M, et al
    Antidiabetic Medication, Statins and the Risk and Prognosis of Non-endometrioid Endometrial Cancer in Women with Type 2 Diabetes.
    Anticancer Res. 2018;38:4169-4178.
    PubMed     Text format     Abstract available


  56. LIAO CL, Chu YL, Lin HY, Chen CY, et al
    Bisdemethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells via Inhibition of NF-kB, MMP-2 and -9 Pathways.
    Anticancer Res. 2018;38:3989-3997.
    PubMed     Text format     Abstract available


    June 2018
  57. JANSSEN S, Hansen HC, Schild SE, Rades D, et al
    An Instrument for Estimating the 6-Month Survival Probability After Whole-brain Irradiation Alone for Cerebral Metastases from Gynecological Cancer.
    Anticancer Res. 2018;38:3753-3756.
    PubMed     Text format     Abstract available


  58. GADDUCCI A, Pistolesi S, Guerrieri ME, Cosio S, et al
    Malignant Transformation in Mature Cystic Teratomas of the Ovary: Case Reports and Review of the Literature.
    Anticancer Res. 2018;38:3669-3675.
    PubMed     Text format     Abstract available


  59. TZAFETAS M, Mitra A, Kalliala I, Lever S, et al
    Fertility-sparing Surgery for Presumed Early-stage Invasive Cervical Cancer: A Survey of Practice in the United Kingdom.
    Anticancer Res. 2018;38:3641-3646.
    PubMed     Text format     Abstract available


  60. GADDUCCI A, Landoni F, Cosio S, Zizioli V, et al
    Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study.
    Anticancer Res. 2018;38:3627-3634.
    PubMed     Text format     Abstract available


  61. KREIENBRING K, Franz A, Richter R, Dragun D, et al
    The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer.
    Anticancer Res. 2018;38:3619-3625.
    PubMed     Text format     Abstract available


  62. CHUNG T, DO SI, Na K, Kim G, et al
    Stromal p16 Overexpression in Gastric-type Mucinous Carcinoma of the Uterine Cervix.
    Anticancer Res. 2018;38:3551-3558.
    PubMed     Text format     Abstract available


  63. AHN SY, Li C, Zhang X, Hyun YM, et al
    Mitofusin-2 Expression Is Implicated in Cervical Cancer Pathogenesis.
    Anticancer Res. 2018;38:3419-3426.
    PubMed     Text format     Abstract available


  64. PIRLAMARLA AK, Tang J, Amin B, Kabarriti R, et al
    Vulvar Melanoma with Isolated Metastasis to the Extraocular Muscles: Case Report and Brief Literature Review.
    Anticancer Res. 2018;38:3763-3766.
    PubMed     Text format     Abstract available


  65. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Text format     Abstract available


    May 2018
  66. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Utilization of Hysterectomy Following Chemoradiation for IB2/IIA2 Cervical Cancer in the National Cancer Data Base.
    Anticancer Res. 2018;38:3175-3179.
    PubMed     Text format     Abstract available


  67. LUMACHI F, Basso SMM, Camozzi V, Spaziante R, et al
    Bone Mineral Density as a Potential Predictive Factor for Luminal-type Breast Cancer in Postmenopausal Women.
    Anticancer Res. 2018;38:3049-3054.
    PubMed     Text format     Abstract available


  68. KISS I, Kolostova K, Matkowski R, Jedryka M, et al
    Correlation Between Disease Stage and the Presence of Viable Circulating Tumor Cells in Endometrial Cancer.
    Anticancer Res. 2018;38:2983-2987.
    PubMed     Text format     Abstract available


  69. PHELIPPEAU J, Rouzier R, Koskas M
    Adherence to Guidelines During Follow-up of Endometrial Cancer: Analysis of French Health Insurance Database.
    Anticancer Res. 2018;38:2977-2982.
    PubMed     Text format     Abstract available


  70. SLETTEN ET, Arnes M, Vereide AB, Orbo A, et al
    Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study.
    Anticancer Res. 2018;38:2883-2889.
    PubMed     Text format     Abstract available


  71. SUNG JY, Jung YY, Kim HS
    Clinicopathological Characteristics and KRAS Mutation Status of Endometrial Mucinous Metaplasia and Carcinoma.
    Anticancer Res. 2018;38:2779-2786.
    PubMed     Text format     Abstract available


  72. LIN CC, Kuo CL, Huang YP, Chen CY, et al
    Demethoxycurcumin Suppresses Migration and Invasion of Human Cervical Cancer HeLa Cells via Inhibition of NF-kappaB Pathways.
    Anticancer Res. 2018;38:2761-2769.
    PubMed     Text format     Abstract available


  73. ARGYRI E, Tsimplaki E, Papatheodorou D, Daskalopoulou D, et al
    Recent Trends in HPV Infection and Type Distribution in Greece.
    Anticancer Res. 2018;38:3079-3084.
    PubMed     Text format     Abstract available


  74. KRAMER B, Kneissle M, Birk R, Rotter N, et al
    Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
    Anticancer Res. 2018;38:2723-2731.
    PubMed     Text format     Abstract available


    April 2018
  75. SCHUSTER S, Joura E, Kohlberger P
    Natural History of Squamous Intraepithelial Lesions in Pregnancy and Mode of Delivery.
    Anticancer Res. 2018;38:2439-2442.
    PubMed     Text format     Abstract available


  76. PERRIN M, Bentivegna E, Bonneau C, Uzan C, et al
    Bevacizumab Does Not Reduce the Lymphocele Rate in Advanced Ovarian Cancer After Complete Cytoreductive Surgery.
    Anticancer Res. 2018;38:2247-2252.
    PubMed     Text format     Abstract available


  77. TRYBUS W, Krol T, Trybus E, Stachurska A, et al
    Induction of Mitotic Catastrophe in Human Cervical Cancer Cells After Administration of Aloe-emodin.
    Anticancer Res. 2018;38:2037-2044.
    PubMed     Text format     Abstract available


    March 2018
  78. GADDUCCI A, Guerrieri ME, Cosio S, Fabrini MG, et al
    Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study.
    Anticancer Res. 2018;38:1695-1703.
    PubMed     Text format     Abstract available


  79. FILIPESCU A, Balescu I, Bacalbasa N
    Upper Abdominal Resection for Isolated Metastatic Lesions in Recurrent Cervical Cancer.
    Anticancer Res. 2018;38:1659-1663.
    PubMed     Text format     Abstract available


  80. STOPE MB, Cernat V, Kaul A, Diesing K, et al
    Functionality of the Tumor Suppressor microRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma.
    Anticancer Res. 2018;38:1547-1550.
    PubMed     Text format     Abstract available


  81. KOENSGEN D, Weiss M, Assmann K, Brucker SY, et al
    Characterization and Management of Borderline Ovarian Tumors - Results of a Retrospective, Single-center Study of Patients Treated at the Department of Gynecology and Obstetrics of the University Medicine Greifswald.
    Anticancer Res. 2018;38:1539-1545.
    PubMed     Text format     Abstract available


  82. CANLORBE G, Touboul C, Chargari C, Bentivegna E, et al
    Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer.
    Anticancer Res. 2018;38:1517-1523.
    PubMed     Text format     Abstract available


  83. FAHLEN M, Zhang H, Lofgren L, Masironi B, et al
    Expression of Progesterone and Androgen Receptors in the Breast of Premenopausal Women, Considering Menstrual Phase.
    Anticancer Res. 2018;38:1499-1510.
    PubMed     Text format     Abstract available


  84. CHUNG EH, Brady PC, Smith KK, Davis MR, et al
    Combined Oocyte Retrieval and Robot-assisted Hysterectomy in a Super Morbidly Obese Patient with Endometrial Carcinoma.
    Anticancer Res. 2018;38:1467-1470.
    PubMed     Text format     Abstract available


  85. FISZER-MALISZEWSKA L, Laczmanski L, Dolinska A, Jagas M, et al
    Polymorphisms of ABCB1, CYP3A4 and CYP3A5 Genes in Ovarian Cancer and Treatment Response in Poles.
    Anticancer Res. 2018;38:1455-1459.
    PubMed     Text format     Abstract available


  86. NA K, Sung JY, Kim HS
    Clinicopathological Characteristics of High-grade Squamous Intraepithelial Lesions Involving Condyloma Acuminatum.
    Anticancer Res. 2018;38:1767-1774.
    PubMed     Text format     Abstract available


    February 2018
  87. HATA M, Koike I, Miyagi E, Asai-Sato M, et al
    Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care.
    Anticancer Res. 2018;38:1033-1040.
    PubMed     Text format     Abstract available


  88. KALAMPOKAS E, Young H, Bednarek A, Habib M, et al
    Surgical Outcomes and Morbidity After Radical Surgery for Ovarian Cancer in Aberdeen Royal Infirmary, the Northeast of Scotland Gynaecologic Oncology Centre.
    Anticancer Res. 2018;38:923-928.
    PubMed     Text format     Abstract available


  89. MATUURA H, Miyamoto M, Takano M, Soyama H, et al
    Low Expression of CD44 Is an Independent Factor of Poor Prognosis in Ovarian Mucinous Carcinoma.
    Anticancer Res. 2018;38:717-722.
    PubMed     Text format     Abstract available


  90. ZHAO Y, Xiong GW, Zhang XW, Hang BO, et al
    Is Ki-67 of Diagnostic Value in Distinguishing Between Partial and Complete Hydatidiform Moles? A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:1105-1110.
    PubMed     Text format     Abstract available


    January 2018
  91. BRUCKNER HW, Gurell D, Hirschfeld A
    Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
    Anticancer Res. 2018;38:547-552.
    PubMed     Text format     Abstract available


  92. OKONOGI N, Wakatsuki M, Kato S, Shiba S, et al
    Long-term Outcomes of Carbon-ion Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Uterine Cervix.
    Anticancer Res. 2018;38:457-463.
    PubMed     Text format     Abstract available


  93. BACALBASA N, Balescu I, Brasoveanu V, Anca AF, et al
    Debulking Surgery for Pelvic Recurrence After Surgically-treated Tubal Gestational Choriocarcinoma - A Case Report and Literature Review.
    Anticancer Res. 2018;38:423-426.
    PubMed     Text format     Abstract available


  94. MIYAMOTO M, Takano M, Aoyama T, Soyama H, et al
    Phenoxodiol Increases Cisplatin Sensitivity in Ovarian Clear Cancer Cells Through XIAP Down-regulation and Autophagy Inhibition.
    Anticancer Res. 2018;38:301-306.
    PubMed     Text format     Abstract available


  95. KOBIERZYCKI C, Piotrowska A, Latkowski K, Zabel M, et al
    Correlation of Pyruvate Kinase M2 Expression with Clinicopathological Data in Ovarian Cancer.
    Anticancer Res. 2018;38:295-300.
    PubMed     Text format     Abstract available


  96. SOUKUP V, Capoun O, Pesl M, Sobotka R, et al
    Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
    Anticancer Res. 2018;38:239-246.
    PubMed     Text format     Abstract available


  97. PELISSIER A, Franke O, Darai E, Houvenaeghel G, et al
    Value of Diaphragmatic Surgery During Interval Debulking Surgery.
    Anticancer Res. 2018;38:411-416.
    PubMed     Text format     Abstract available


    December 2017
  98. LEE HJ, Lee YH, Chong GO, Hong DG, et al
    Robotic-assisted Transperitoneal Infrarenal Para-aortic Lymphadenectomy for Gynecological Malignancies: Comparison with a Laparoscopic Approach.
    Anticancer Res. 2017;37:7087-7093.
    PubMed     Text format     Abstract available


  99. NIIBE Y, Onda T, Matsuo K, Inoue Y, et al
    Phase II Study of Concurrent Chemoradiotheapy Using Nedaplatin for Locally Advanced Uterine Cervical Carcinoma (KGROG0501): Final Results.
    Anticancer Res. 2017;37:6983-6988.
    PubMed     Text format     Abstract available


  100. MOURAD WF, Packianathan S, Yan W, Pishgou M, et al
    Reliable Radiation Technique to Minimize Ovarian Dose During Radiation Prophylaxis of Heterotopic Ossification.
    Anticancer Res. 2017;37:6929-6935.
    PubMed     Text format     Abstract available


  101. TINELLI G, Cappuccio S, Parente E, Fagotti A, et al
    Resectability and Vascular Management of Retroperitoneal Gynecological Malignancies: A Large Single-institution Case-Series.
    Anticancer Res. 2017;37:6899-6906.
    PubMed     Text format     Abstract available


  102. DUCOULOMBIER S, Golfier F, Colomban O, Benayoun D, et al
    Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.
    Anticancer Res. 2017;37:6879-6886.
    PubMed     Text format     Abstract available


  103. KOENSGEN D, Besic I, Gumbel D, Kaul A, et al
    Cold Atmospheric Plasma (CAP) and CAP-Stimulated Cell Culture Media Suppress Ovarian Cancer Cell Growth - A Putative Treatment Option in Ovarian Cancer Therapy.
    Anticancer Res. 2017;37:6739-6744.
    PubMed     Text format     Abstract available


  104. NA K, Sung JY, Kim HS
    TP53 Mutation Status of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma with a Wild-type p53 Immunostaining Pattern.
    Anticancer Res. 2017;37:6697-6703.
    PubMed     Text format     Abstract available


  105. KUITTINEN T, Rovio P, Staff S, Luukkaala T, et al
    Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro.
    Anticancer Res. 2017;37:6575-6581.
    PubMed     Text format     Abstract available


  106. RAPI V, Dogan A, Schultheis B, Hartmann F, et al
    Melanoma of the Vagina: Case Report and Systematic Review of the Literature.
    Anticancer Res. 2017;37:6911-6920.
    PubMed     Text format     Abstract available


  107. BAVELLONI A, Ramazzotti G, Poli A, Piazzi M, et al
    MiRNA-210: A Current Overview.
    Anticancer Res. 2017;37:6511-6521.
    PubMed     Text format     Abstract available


    November 2017
  108. KIM SM, Rhee YH, Kim JS
    The Anticancer Effects of Radachlorin-mediated Photodynamic Therapy in the Human Endometrial Adenocarcinoma Cell Line HEC-1-A.
    Anticancer Res. 2017;37:6251-6258.
    PubMed     Text format     Abstract available


  109. YANG Y, Li X, Mamouni K, Kucuk O, et al
    Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer.
    Anticancer Res. 2017;37:6235-6243.
    PubMed     Text format     Abstract available


  110. NAKATANI M, Watari H, Mitamura T, Wang L, et al
    The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo.
    Anticancer Res. 2017;37:6125-6132.
    PubMed     Text format     Abstract available


  111. TRYBUS W, Krol T, Trybus E, Kopacz-Bednarska A, et al
    Changes in the Lysosomal System of Cervical Cancer Cells Induced by Emodin Action.
    Anticancer Res. 2017;37:6087-6096.
    PubMed     Text format     Abstract available


  112. GADDUCCI A, Guerrieri ME
    Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    Anticancer Res. 2017;37:5955-5965.
    PubMed     Text format     Abstract available


    October 2017

  113. Translational Advances in Gynecologic Cancers. 1st Edition.
    Anticancer Res. 2017;37:5907.
    PubMed     Text format    


  114. BACALBASA N, Balescu I, Filipescu A
    Debulking Surgery for Clear Cell Carcinoma of the Ovary - A Case Report and Literature Review.
    Anticancer Res. 2017;37:5707-5711.
    PubMed     Text format     Abstract available


  115. SHIBA S, Okonogi N, Kato S, Wakatsuki M, et al
    Clinical Impact of Re-irradiation with Carbon-ion Radiotherapy for Lymph Node Recurrence of Gynecological Cancers.
    Anticancer Res. 2017;37:5577-5583.
    PubMed     Text format     Abstract available


  116. PARK CK, Kim HS
    Clinicopathological Characteristics of Ovarian Sclerosing Stromal Tumor with an Emphasis on TFE3 Overexpression.
    Anticancer Res. 2017;37:5441-5447.
    PubMed     Text format     Abstract available


  117. GLASSMAN D, Hignett S, Rehman S, Linforth R, et al
    Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.
    Anticancer Res. 2017;37:5329-5341.
    PubMed     Text format     Abstract available


  118. KAWAHARA H, Akiba T, Yanaga K
    Transanal Assisted Resection with Closure of Anal Canal for Lower Rectal Diseases.
    Anticancer Res. 2017;37:5767-5769.
    PubMed     Text format     Abstract available


  119. GUNGORDUK K, Asicioglu O, Braicu EI, Almuheimid J, et al
    The Impact of Surgical Staging on the Prognosis of Mucinous Borderline Tumors of the Ovaries: A Multicenter Study.
    Anticancer Res. 2017;37:5609-5616.
    PubMed     Text format     Abstract available


    September 2017
  120. ANNEDE P, Darreon J, Benkemouche A, Valdenaire S, et al
    Flattening Filter Free vs. Flattened Beams for Lung Stereotactic Body Radiation Therapy.
    Anticancer Res. 2017;37:5133-5139.
    PubMed     Text format     Abstract available


  121. VORA M, Alattia LA, Ansari J, Ong M, et al
    Nicotinamide Phosphoribosyl Transferase a Reliable Marker of Progression in Cervical Dysplasia.
    Anticancer Res. 2017;37:4821-4825.
    PubMed     Text format     Abstract available


  122. SUKOVAS A, Cesna V, Jasukaitiene A, Barauskas G, et al
    Response of OVCAR-3 Cells to Cisplatin and Hyperthermia: Does Hyperthermia Really Matter?
    Anticancer Res. 2017;37:5011-5018.
    PubMed     Text format     Abstract available


  123. KASE S, Ishijima K, Uraki T, Suimon Y, et al
    Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa.
    Anticancer Res. 2017;37:5001-5004.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: